[Form 4] PLUS THERAPEUTICS, Inc. Insider Trading Activity
Reporting person: An van Es-Johansson, identified as a Director of PLUS THERAPEUTICS, Inc. (PSTV). Transaction: on 08/13/2025 the reporting person was granted 297,794 stock options with an exercise price of $0.5744. The options vest monthly over 12 months from the grant date in substantially equal installments and vest in full at the issuer's 2026 annual stockholder meeting if the reporting person remains in service. The options expire on 08/12/2035 and the report shows 297,794 underlying common shares beneficially owned following the transaction in a direct ownership form. The Form 4 was signed by an attorney-in-fact.
Persona che ha segnalato: An van Es-Johansson, identificata come Direttore di PLUS THERAPEUTICS, Inc. (PSTV). Operazione: in data 13/08/2025 alla persona segnalante sono state concesse 297.794 stock option con prezzo di esercizio di $0,5744. Le opzioni maturano mensilmente in 12 rate sostanzialmente uguali a partire dalla data di assegnazione e maturano integralmente in occasione dell'assemblea annuale degli azionisti dell'emittente del 2026 se la persona segnalante rimane in carica. Le opzioni scadono il 12/08/2035 e il rapporto indica 297.794 azioni comuni sottostanti possedute beneficiariamente a seguito dell'operazione in forma di propriet脿 diretta. Il Modulo 4 猫 stato firmato da un procuratore.
Persona informante: An van Es-Johansson, identificada como Directora de PLUS THERAPEUTICS, Inc. (PSTV). 罢谤补苍蝉补肠肠颈贸苍: el 13/08/2025 a la persona informante se le concedieron 297.794 opciones sobre acciones con un precio de ejercicio de $0,5744. Las opciones se adquieren mensualmente en 12 cuotas sustancialmente iguales desde la fecha de concesi贸n y se consolidan en su totalidad en la junta anual de accionistas del emisor de 2026 si la persona informante permanece en servicio. Las opciones expiran el 12/08/2035 y el informe muestra 297.794 acciones ordinarias subyacentes propiedad beneficiaria tras la transacci贸n en forma de propiedad directa. El Formulario 4 fue firmado por un apoderado.
鞁犼碃鞚�: PLUS THERAPEUTICS, Inc.(PSTV)鞚� 鞚挫偓搿� 頇曥澑霅� An van Es-Johansson. 瓯半灅: 2025雲� 8鞗� 13鞚� 鞁犼碃鞚胳棎瓴� 頄夓偓臧�瓴� $0.5744鞚� 297,794欤� 靸侂嫻鞚� 鞀ろ啞鞓奠厴鞚� 攵�鞐悩鞐堨姷雼堧嫟. 頃措嫻 鞓奠厴鞚� 攵�鞐澕搿滊秬韯� 12臧滌洈鞐� 瓯胳硱 鞁れ鞝侅溂搿� 霃欖澕頃� 旮堨暋鞙茧 毵れ洈 旆摑霅橂┌, 鞁犼碃鞚胳澊 瓿勳啀 攴茧 欷戩澑 瓴届毎 氚滍枆須岇偓鞚� 2026雲� 鞐半 欤检＜齑濏殞鞐愳劀 鞝勲秬 旆摑霅╇媹雼�. 鞓奠厴鞚� 毵岆鞚检潃 2035雲� 8鞗� 12鞚�鞚措┌, 氤搓碃靹滌棎電� 瓯半灅 頉� 297,794欤检潣 旮办磮 氤错喌欤�毳� 歆侅爲 靻岇湢 順曧儨搿� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堧姅 瓴冹溂搿� 響滌嫓霅橃柎 鞛堨姷雼堧嫟. Form 4電� 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.
Personne d茅clarante : An van Es-Johansson, identifi茅e comme directrice de PLUS THERAPEUTICS, Inc. (PSTV). Op茅ration : le 13/08/2025, il/elle s'est vu(e) accorder 297 794 options d'achat au prix d'exercice de 0,5744 $. Les options acqui猫rent des droits mensuellement sur 12 mois 脿 compter de la date d'attribution en versements substantiellement 茅gaux et s'acqui猫rent int茅gralement lors de l'assembl茅e g茅n茅rale annuelle des actionnaires de l'茅metteur en 2026 si la personne d茅clarante demeure en fonction. Les options expireront le 12/08/2035 et le rapport indique 297 794 actions ordinaires sous-jacentes d茅tenues 脿 titre b茅n茅ficiaire apr猫s l'op茅ration sous forme de propri茅t茅 directe. Le Formulaire 4 a 茅t茅 sign茅 par un mandataire.
Meldende Person: An van Es-Johansson, identifiziert als Direktorin von PLUS THERAPEUTICS, Inc. (PSTV). Transaktion: Am 13.08.2025 wurden der meldenden Person 297.794 Aktienoptionen mit einem Aus眉bungspreis von $0,5744 gew盲hrt. Die Optionen werden 眉ber 12 Monate ab dem Gew盲hrungsdatum monatlich in im Wesentlichen gleichen Raten unverfallbar und fallen vollst盲ndig bei der Hauptversammlung des Emittenten 2026 an, sofern die meldende Person weiterhin im Dienst ist. Die Optionen verfallen am 12.08.2035 und der Bericht weist nach der Transaktion 297.794 zugrundeliegende Stammaktien als vorteilhaft gehalten in Form direkten Eigentums aus. Das Formular 4 wurde von einem Bevollm盲chtigten unterschrieben.
- Equity alignment: Director received 297,794 options, aligning incentives with long-term shareholder value through time-based vesting
- Clear vesting schedule: Options vest monthly over 12 months and fully vest at the 2026 annual meeting, providing predictable service-based vesting
- Potential dilution: Grant represents 297,794 underlying shares that could increase the company鈥檚 outstanding share count if exercised
- No disclosure of total outstanding share count: The Form 4 does not state company-wide share totals, limiting assessment of the grant鈥檚 proportional impact
Insights
TL;DR: Board-level equity grant aligns director incentives with shareholders through time-based vesting, typical for non-employee directors.
This Form 4 documents a time-based equity award to a director consisting of 297,794 options at a $0.5744 exercise price, vesting monthly over one year and accelerating to full vesting at the 2026 annual meeting subject to continued service. From a governance perspective, the structure is standard: multi-year economic exposure is created while requiring continued service to realize value. The filing is informative about dilution potential but does not disclose any acceleration triggers beyond the stated vesting schedule.
TL;DR: This is a routine director option grant; watch potential dilution if options are exercised but no immediate cash impact until exercise.
The disclosure shows 297,794 options exercisable at $0.5744 and expiring on 08/12/2035. The options represent future potential issuance of common stock if exercised; the Form 4 records these as directly beneficially owned post-grant. There is no additional information about cash proceeds, hedging, or transfers. The item does not include other changes to outstanding share count or material corporate events.
Persona che ha segnalato: An van Es-Johansson, identificata come Direttore di PLUS THERAPEUTICS, Inc. (PSTV). Operazione: in data 13/08/2025 alla persona segnalante sono state concesse 297.794 stock option con prezzo di esercizio di $0,5744. Le opzioni maturano mensilmente in 12 rate sostanzialmente uguali a partire dalla data di assegnazione e maturano integralmente in occasione dell'assemblea annuale degli azionisti dell'emittente del 2026 se la persona segnalante rimane in carica. Le opzioni scadono il 12/08/2035 e il rapporto indica 297.794 azioni comuni sottostanti possedute beneficiariamente a seguito dell'operazione in forma di propriet脿 diretta. Il Modulo 4 猫 stato firmato da un procuratore.
Persona informante: An van Es-Johansson, identificada como Directora de PLUS THERAPEUTICS, Inc. (PSTV). 罢谤补苍蝉补肠肠颈贸苍: el 13/08/2025 a la persona informante se le concedieron 297.794 opciones sobre acciones con un precio de ejercicio de $0,5744. Las opciones se adquieren mensualmente en 12 cuotas sustancialmente iguales desde la fecha de concesi贸n y se consolidan en su totalidad en la junta anual de accionistas del emisor de 2026 si la persona informante permanece en servicio. Las opciones expiran el 12/08/2035 y el informe muestra 297.794 acciones ordinarias subyacentes propiedad beneficiaria tras la transacci贸n en forma de propiedad directa. El Formulario 4 fue firmado por un apoderado.
鞁犼碃鞚�: PLUS THERAPEUTICS, Inc.(PSTV)鞚� 鞚挫偓搿� 頇曥澑霅� An van Es-Johansson. 瓯半灅: 2025雲� 8鞗� 13鞚� 鞁犼碃鞚胳棎瓴� 頄夓偓臧�瓴� $0.5744鞚� 297,794欤� 靸侂嫻鞚� 鞀ろ啞鞓奠厴鞚� 攵�鞐悩鞐堨姷雼堧嫟. 頃措嫻 鞓奠厴鞚� 攵�鞐澕搿滊秬韯� 12臧滌洈鞐� 瓯胳硱 鞁れ鞝侅溂搿� 霃欖澕頃� 旮堨暋鞙茧 毵れ洈 旆摑霅橂┌, 鞁犼碃鞚胳澊 瓿勳啀 攴茧 欷戩澑 瓴届毎 氚滍枆須岇偓鞚� 2026雲� 鞐半 欤检＜齑濏殞鞐愳劀 鞝勲秬 旆摑霅╇媹雼�. 鞓奠厴鞚� 毵岆鞚检潃 2035雲� 8鞗� 12鞚�鞚措┌, 氤搓碃靹滌棎電� 瓯半灅 頉� 297,794欤检潣 旮办磮 氤错喌欤�毳� 歆侅爲 靻岇湢 順曧儨搿� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堧姅 瓴冹溂搿� 響滌嫓霅橃柎 鞛堨姷雼堧嫟. Form 4電� 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.
Personne d茅clarante : An van Es-Johansson, identifi茅e comme directrice de PLUS THERAPEUTICS, Inc. (PSTV). Op茅ration : le 13/08/2025, il/elle s'est vu(e) accorder 297 794 options d'achat au prix d'exercice de 0,5744 $. Les options acqui猫rent des droits mensuellement sur 12 mois 脿 compter de la date d'attribution en versements substantiellement 茅gaux et s'acqui猫rent int茅gralement lors de l'assembl茅e g茅n茅rale annuelle des actionnaires de l'茅metteur en 2026 si la personne d茅clarante demeure en fonction. Les options expireront le 12/08/2035 et le rapport indique 297 794 actions ordinaires sous-jacentes d茅tenues 脿 titre b茅n茅ficiaire apr猫s l'op茅ration sous forme de propri茅t茅 directe. Le Formulaire 4 a 茅t茅 sign茅 par un mandataire.
Meldende Person: An van Es-Johansson, identifiziert als Direktorin von PLUS THERAPEUTICS, Inc. (PSTV). Transaktion: Am 13.08.2025 wurden der meldenden Person 297.794 Aktienoptionen mit einem Aus眉bungspreis von $0,5744 gew盲hrt. Die Optionen werden 眉ber 12 Monate ab dem Gew盲hrungsdatum monatlich in im Wesentlichen gleichen Raten unverfallbar und fallen vollst盲ndig bei der Hauptversammlung des Emittenten 2026 an, sofern die meldende Person weiterhin im Dienst ist. Die Optionen verfallen am 12.08.2035 und der Bericht weist nach der Transaktion 297.794 zugrundeliegende Stammaktien als vorteilhaft gehalten in Form direkten Eigentums aus. Das Formular 4 wurde von einem Bevollm盲chtigten unterschrieben.
FAQ
What did the Form 4 for PSTV report on 08/13/2025?
What is the vesting schedule for the options reported in the PSTV Form 4?
When do the options expire according to the Form 4?
How many shares are shown as beneficially owned after the transaction?
What is the exercise price of the options reported for PSTV?
